VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+23.52%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$625M
AUM Growth
+$625M
(+22%)
Cap. Flow
+$66.7M
Cap. Flow
% of AUM
10.67%
Top 10 Holdings %
Top 10 Hldgs %
69.45%
Holding
35
New
10
Increased
5
Reduced
4
Closed
5
Top Buys
| 1 |
4D Molecular Therapeutics
FDMT
|
$54.2M |
| 2 |
Dyne Therapeutics
DYN
|
$24.5M |
| 3 |
Pharvaris
PHVS
|
$20.1M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$18M |
| 5 |
Oric Pharmaceuticals
ORIC
|
$16.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Viridian Therapeutics
VRDN
$1.5B
| $73.3M | 11.73% | 3,082,622 +382,757 | +14% | +$9.11M |
|
2
Cogent Biosciences
COGT
$1.69B
| $55.5M | 8.87% | 4,684,132 -200,845 | -4% | -$2.38M |
|
|
3
4D Molecular Therapeutics
FDMT
$288M
| $54.2M | 8.67% | +3,000,000 | New | +$54.2M |
|
4
Enliven Therapeutics
ELVN
$1.2B
| $45.5M | 7.28% | 2,230,127 +15,985 | +0.7% | +$326K |
|
5
Merus
MRUS
$4.98B
| $45.5M | 7.27% | 1,726,214 +500,000 | +41% | +$13.2M |
|
6
GH Research
GHRS
$837M
| $41.7M | 6.67% | 3,517,125 | – | – |
|
|
AMAM
7
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $40.9M | 6.54% | 2,484,960 -813,617 | -25% | -$13.4M |
|
8
KalVista Pharmaceuticals
KALV
$678M
| $26.3M | 4.2% | 2,916,667 | – | – |
|
9
Terns Pharmaceuticals
TERN
$609M
| $26M | 4.16% | 2,972,869 -646,653 | -18% | -$5.66M |
|
10
Cabaletta Bio
CABA
$133M
| $25.5M | 4.07% | 1,973,251 | – | – |
|
|
11
Dyne Therapeutics
DYN
$1.92B
| $24.5M | 3.91% | +2,173,913 | New | +$24.5M |
|
12
Celcuity
CELC
$2.17B
| $23.1M | 3.7% | 2,105,386 | – | – |
|
13
Savara
SVRA
$567M
| $20.3M | 3.25% | 6,351,531 | – | – |
|
|
14
Pharvaris
PHVS
$1.39B
| $20.1M | 3.21% | +1,326,200 | New | +$20.1M |
|
|
15
Rhythm Pharmaceuticals
RYTM
$6.85B
| $18M | 2.87% | +1,090,000 | New | +$18M |
|
|
16
Oric Pharmaceuticals
ORIC
$994M
| $16.6M | 2.66% | +2,142,856 | New | +$16.6M |
|
17
Aclaris Therapeutics
ACRS
$209M
| $10.8M | 1.73% | 1,040,754 | – | – |
|
18
Trevi Therapeutics
TRVI
$883M
| $8.18M | 1.31% | 3,422,397 +372,375 | +12% | +$890K |
|
19
Applied Therapeutics
APLT
$71M
| $7.24M | 1.16% | +5,658,034 | New | +$7.24M |
|
|
THRX
20
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $7.18M | 1.15% | 770,000 | – | – |
|
21
Milestone Pharmaceuticals
MIST
$156M
| $6.3M | 1.01% | 2,208,812 | – | – |
|
22
Adverum Biotechnologies
ADVM
$64.6M
| $6.18M | 0.99% | +3,886,246 | New | +$6.18M |
|
23
Praxis Precision Medicines
PRAX
$958M
| $6.1M | 0.98% | +5,304,410 | New | +$6.1M |
|
24
Pliant Therapeutics
PLRX
$101M
| $5.24M | 0.84% | 288,949 -1,141,051 | -80% | -$20.7M |
|
25
Lyra Therapeutics
LYRA
$11.5M
| $3.8M | 0.61% | 924,170 | – | – |
|